In a new draft guidance, the US Food and Drug Administration (FDA) outlined the types of confirmatory evidence it will accept from sponsors that want to use one adequate and well-controlled clinical investigation to demonstrate drug effectiveness.
FDA announced that the guidance “provides additional information on the flexibility in the amount and type of evidence needed to establish their effectiveness.” The change is meant to accommodate more products for serious diseases that lack effective treatments…
